Literature DB >> 14696971

Multinucleated osteoclast formation in vivo and in vitro by P2X7 receptor-deficient mice.

A Gartland1, K A Buckley, R A Hipskind, M J Perry, J H Tobias, G Buell, I Chessell, W B Bowler, J A Gallagher.   

Abstract

The P2X7 receptor is a member of the family of P2X purinergic receptors, which upon sustained activation forms large pores in the plasma membrane. In cells of hematopoietic origin, P2X7 receptor activation has been shown to lead to multiple downstream events, including cytokine release, cell permeabilization, and apoptosis. This receptor has also been implicated in the generation of multinucleated giant cells, polykaryons, and osteoclasts. We have recently demonstrated that a blockade of this receptor inhibits osteoclast formation in vitro; therefore, we examined mice deficient in the P2X7 receptor in the context of bone. These mice were healthy and displayed no overt skeletal problems. Furthermore, we were able to demonstrate their ability to form multinucleated cells, in particular osteoclasts, both in vivo and in vitro. We also demonstrate the ability of P2X7R-/- multinucleated osteoclasts, upon stimulation with maitotoxin (MTX), to form pores in the plasma membrane in vitro. These findings are consistent with the existence of an endogenous pore structure present in osteoclast precursor cells that can be activated either by the P2X7 receptor, or in its absence, by alternative signals to mediate fusion and pore formation. These data provide further insight into the mode of action of the P2X7 receptor.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14696971     DOI: 10.1615/critreveukaryotgeneexpr.v13.i24.150

Source DB:  PubMed          Journal:  Crit Rev Eukaryot Gene Expr        ISSN: 1045-4403            Impact factor:   1.807


  35 in total

Review 1.  Molecular and functional properties of P2X receptors--recent progress and persisting challenges.

Authors:  Karina Kaczmarek-Hájek; Eva Lörinczi; Ralf Hausmann; Annette Nicke
Journal:  Purinergic Signal       Date:  2012-05-01       Impact factor: 3.765

Review 2.  Pharmacology of P2X channels.

Authors:  Joel R Gever; Debra A Cockayne; Michael P Dillon; Geoffrey Burnstock; Anthony P D W Ford
Journal:  Pflugers Arch       Date:  2006-04-29       Impact factor: 3.657

Review 3.  Purinergic signalling in the musculoskeletal system.

Authors:  Geoffrey Burnstock; Timothy R Arnett; Isabel R Orriss
Journal:  Purinergic Signal       Date:  2013-08-14       Impact factor: 3.765

4.  Role of the P2X7 receptor in the osteogenic differentiation of mesenchymal cells and in osteoclast fusion : presented by: Maria P. Abbracchio.

Authors:  Ning Wang; Alison Gartland
Journal:  Purinergic Signal       Date:  2013-09       Impact factor: 3.765

5.  Functional polymorphisms in the P2X7 receptor gene are associated with osteoporosis.

Authors:  L B Husted; T Harsløf; L Stenkjær; M Carstens; N R Jørgensen; B L Langdahl
Journal:  Osteoporos Int       Date:  2012-06-16       Impact factor: 4.507

6.  Reduced bone turnover in mice lacking the P2Y13 receptor of ADP.

Authors:  Ning Wang; Bernard Robaye; Ankita Agrawal; Timothy M Skerry; Jean-Marie Boeynaems; Alison Gartland
Journal:  Mol Endocrinol       Date:  2011-11-22

Review 7.  Updating osteoimmunology: regulation of bone cells by innate and adaptive immunity.

Authors:  Matthew C Walsh; Noriko Takegahara; Hyunsoo Kim; Yongwon Choi
Journal:  Nat Rev Rheumatol       Date:  2018-01-11       Impact factor: 20.543

8.  Recent advances in understanding the mechanisms of osteoclast precursor fusion.

Authors:  Merry Jo Oursler
Journal:  J Cell Biochem       Date:  2010-08-01       Impact factor: 4.429

9.  P2X7 receptors regulate multiple types of membrane trafficking responses and non-classical secretion pathways.

Authors:  Yan Qu; George R Dubyak
Journal:  Purinergic Signal       Date:  2009-02-03       Impact factor: 3.765

10.  Expression, signaling, and function of P2X7 receptors in bone.

Authors:  Matthew W Grol; Nattapon Panupinthu; Jasminka Korcok; Stephen M Sims; S Jeffrey Dixon
Journal:  Purinergic Signal       Date:  2009-02-18       Impact factor: 3.765

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.